Who’s Going to CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

296 organizations and 501 people on the program at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, a ~1,700-person, evenly mixed industry & academic meeting of Alzheimer’s trial sponsors, trialists and biomarker teams. As of Nov 12, 2026.

Format
Topic
Top represented
Showing 1–3 of 296 organizations
OrganizationCTAD 2026 Attendance
Mass General Brigham
Boston, Massachusetts
Hospitals & health systems
Boston health system that includes Massachusetts General and Brigham and Women's hospitals; runs large Alzheimer's research and trial programmes.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Point-of-Care Low-Field MRI for Monitoring ARIA-E and Pseudoatrophy During Anti-Amyloid Therapy (P087)
PET and MRI imaging · Anti-amyloid and anti-tau therapies
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Talk
Mon Nov 16
4:35pm
Poster
Thu Nov 19
7:15am–5:00pm
Poster
Thu Nov 19
7:15am–5:00pm
Poster
Thu Nov 19
7:15am–5:00pm
Poster
Thu Nov 19
7:15am–5:00pm
Poster
Thu Nov 19
7:15am–5:00pm
Massachusetts General Hospital
Boston, Massachusetts
Hospitals & health systems
Harvard teaching hospital in Boston with an NIA-funded Alzheimer's Disease Research Center and the Martinos Center for brain imaging.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort (P107)
Anti-amyloid and anti-tau therapies · PET and MRI imaging · Rising Stars Showcase
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE ɛ4 selectively influence lobar microhemorrhages (P108)
PET and MRI imaging · Anti-amyloid and anti-tau therapies · Rising Stars Showcase
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Talk
Tue Nov 17
2:20pm
Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments
Digital assessment and AI · Prevention and early disease
Poster
Wed Nov 18
7:15am–5:30pm
Utility of plasma pTau217 for cohort enrichment and outcome measurement in prevention trials (P284)
Blood and CSF biomarkers · Prevention and early disease
Poster
Wed Nov 18
7:15am–5:30pm
Poster
Wed Nov 18
7:15am–5:30pm
Poster
Thu Nov 19
7:15am–5:00pm
Poster
Thu Nov 19
7:15am–5:00pm
Universities & institutes
Leads the DIAN network and DIAN-TU trials in inherited Alzheimer's disease, and runs the Knight Alzheimer Disease Research Center.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Session
Mon Nov 16
4:50pm–5:30pm
Poster
Thu Nov 19
7:15am–5:00pm
Smart Triage for Amyloid-Targeting Therapies (STATT) (P499)
Real-world data and access · Anti-amyloid and anti-tau therapies
Talk
Thu Nov 19
1:05pm
Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study
Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from organizations at CTAD 2026

Tell us what you sell and we’ll find the people at these organizations most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

When and where is CTAD 2026?

19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference runs November 16–19, 2026, at Boston Marriott Copley Place in Boston, MA.

Where is the CTAD 2026 program?

This guide lists every organization on the CTAD 2026 program with its sessions; the full program is on the official website.

How do I register for CTAD 2026?

Fees and registration are on the organizer's registration page.

What is CTAD 2026?

CTAD 2026 is the 19th Clinical Trials on Alzheimer’s Disease conference, held November 16–19, 2026 at the Boston Marriott Copley Place in Boston. It is a single-room meeting for Alzheimer’s clinical research: drug developers, academic trialists, regulators and the biomarker, imaging, digital and trial-services companies that support their studies, with sessions on anti-amyloid and anti-tau therapies, blood biomarkers, imaging, trial design and prevention.

What is in this guide?

Every organization we can place at CTAD 2026: the employers of the 501 people on the public program — speakers, symposium chairs and poster presenters across 581 program rows, 480 of them posters — and the 35 sponsors with their level (1 Ultimate, 4 Platinum, 7 Gold, 23 Silver). 296 organizations in one list. A talk or poster counts one person: a poster’s named presenter, or an oral communication’s first author (the program names no presenter for those), never a co-author. People appear as a role and a count, never by name.

Where does this list come from?

Three public pages from the organizer: the final program PDF (sessions and the full poster list), the poster list PDF and the sponsor page. Which organization each printed affiliation names, and what kind of organization it is, was judged from that text; short descriptions state what is well established about an organization. Nothing here requires a login.

How are organizations typed?

Universities and research institutes; hospitals, health systems and clinical trial sites; drug developers (large pharma and biotech); vendors (biomarker and diagnostics companies, digital assessment and AI companies, CROs and trial services, consultancies); and government agencies, foundations and non-profits. The topic filters are judged from each talk’s and poster’s title and the poster list’s own sections.

How current is it?

Pulled on November 12, 2026, about one week before the meeting, from the program and poster list CTAD re-issued on November 12 and from the sponsor page. CTAD publishes no booth numbers or attendee list, and late-breaking sessions can still be added.

Why are there no names?

This guide is about which organizations are in the room, not which people. It never publishes a person’s name.

Browse CTAD 2026 by

Organizations with their own page

138 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction